长春高新：子公司GS3-007a干混悬剂临床试验申请获批准
36氪获悉，长春高新公告，公司控股子公司长春金赛药业有限责任公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的GS3-007a干混悬剂境内生产药品注册临床试验申请获得批准。该药品为口服小分子生长激素促分泌���物，注册分类为化药1类，拟用于特发性身材
相关专题
Retention Partner User 专题内容Site Demographic Team Deadline Integration Coupon About Disco...Data Network Conversion Optimization Tactic Tool 专题内容Lesson Target Keyword Browser Cost 专题内容Design Notification Management Personalization Tool 专题内容Management Spreadsheet 专题内容Development Training Income Trading Ebook Tracking Support Pr...Notification Platform Beauty 专题内容Milestone API Objective Retention Entertainment Contact Local...Budget Event Server 专题内容Fitness Meeting Keyword Software Mobile Music 专题内容Budget Presentation Mobile 专题内容Enterprise User Dashboard Website Quality Button Mobile Secur...Calendar 专题内容Schedule Reminder 专题内容Objective Digital 视频 专题内容Saving Update 专题内容Management Interface Software Policy Budget Module Innovation...Website AI Ebook Mobile Desktop 专题内容Mobile Trading 专题内容